Indications › Diabetes (unspecified) › semaglutide

semaglutide in diabetes (unspecified)

semaglutide is not approved in the US for diabetes (unspecified), and has 38 trials on file here in this condition. 33 of them are phase 3 or later. The next scheduled result is 2026-12. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

38 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in diabetes (unspecified), 9 of them still active and 4 in phase 3. The next is due to report 2026-12-31.

Trials on file: 38
Active: 9
Active phase 3: 4
Participants in active trials: 1,068
Sponsors: 13
Scheduled readouts: 6

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2026-12-31	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) NCT06959784 · China-Japan Friendship Hospital	P4	142
2027-07	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis NCT07017270 · Unity Health Toronto	P4	100
2027-12	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation NCT05702931 · Rigshospitalet, Denmark	P4	104
2028-06	Semaglutide Treatment in Type 1 Diabetes NCT06909006 · Nordsjaellands Hospital	P3	122
2028-07	Impact GLP-1 Agonists Following Bariatric NCT06132477 · University of Missouri-Columbia	P4	150
2028-12-31	New Triple Therapy in Newly Diagnosed Type 2 Diabetes NCT06946628 · Sun Yat-sen University	P3	296

All trials on file

Every registered trial of semaglutide grouped under diabetes (unspecified), largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes NCT01720446	Completed	P3	Novo Nordisk A/S
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes NCT02692716	Completed	P3	Novo Nordisk A/S
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes NCT02607865	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes NCT01930188	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. NCT02648204	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes NCT02128932	Completed	P3	Novo Nordisk A/S
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity NCT05579977	Terminated	P2	Pfizer
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) NCT03061214	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus NCT02863328	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes NCT01885208	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes NCT03136484	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin NCT03021187	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus NCT02863419	Completed	P3	Novo Nordisk A/S
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes NCT02461589	Completed	P2	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only NCT02906930	Completed	P3	Novo Nordisk A/S
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes NCT01923181	Completed	P2	Novo Nordisk A/S
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes NCT02207374	Completed	P3	Novo Nordisk A/S
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes NCT03191396	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. NCT02849080	Completed	P3	Novo Nordisk A/S
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes NCT03015220	Completed	P3	Novo Nordisk A/S
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide NCT00696657	Completed	P2	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes NCT02305381	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes NCT02054897	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment NCT02827708	Completed	P3	Novo Nordisk A/S
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes NCT02254291	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus NCT03086330	Completed	P3	Novo Nordisk A/S
New Triple Therapy in Newly Diagnosed Type 2 Diabetes NCT06946628	Not yet recruiting	P3	Sun Yat-sen University
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes NCT03018028	Completed	P3	Novo Nordisk A/S
Impact GLP-1 Agonists Following Bariatric NCT06132477	Recruiting	P4	University of Missouri-Columbia
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) NCT06959784	Enrolling by invitation	P4	China-Japan Friendship Hospital
The POST-ACS Study NCT05322200	Unknown	P4	Swansea Bay University Health Board
Semaglutide Treatment in Type 1 Diabetes NCT06909006	Not yet recruiting	P3	Nordsjaellands Hospital
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes NCT06762314	Completed	P2	Mostafa Bahaa
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation NCT05702931	Recruiting	P4	Rigshospitalet, Denmark
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis NCT07017270	Recruiting	P4	Unity Health Toronto
Semaglutide 2.4 mg in Patients With Poor Weight-loss NCT05073835	Active, not recruiting	P3	University College, London
Semaglutide vs Sitagliptin NCT05195944	Enrolling by invitation	P4	University Health Network, Toronto
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide NCT06387199	Recruiting	P2/P3	McGill University Health Centre/Research Institute of the McGill University Health Centre

See the full record for semaglutide, or every molecule being studied in diabetes (unspecified). These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.

Get the briefing

semaglutide in diabetes (unspecified)

Scheduled to report

All trials on file